Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with XXXX .

@entity1 @entity2298 @entity2353 @entity1007 @entity1674 @entity22208 @entity165
OBJECTIVE: To assess the effect of replacing protease inhibitors (PIs) with @entity22208 on insulin sensitivity and plasma lipids. - DESIGN: Pilot study including 31 @entity1 with sustained virological control on their first PI-containing HAART regimen. 16 @entity1 were switched from PIs to @entity22208 (ABC group), 15 @entity1 continued on PIs (PI group). In all @entity1 , @entity2353 -analogue reverse transcriptase inhibitors were continued. METHODS: Insulin sensitivity (using an intravenous insulin tolerance test) and fasting total @entity165 and @entity1674 were determined at baseline, month 3, 6, 9 and 12. RESULTS: In the ABC group, there was a significant increase in median insulin sensitivity from baseline within 6 months (+ 49 micromol/l/min), and a significant decrease in both @entity1674 (-41mg/dl) and @entity165 (-40mg/dl) at month 3. These changes were sustained through month 12. In addition, a reversal of baseline insulin resistance, @entity1007 and @entity2298 was observed in the majority of @entity1 . In the PI group, no significant changes in insulin sensitivity, @entity1674 and @entity165 were observed. There was a significant correlation between the changes in insulin sensitivity, @entity1674 and @entity165 . INTERPRETATION: Switching from PIs to @entity22208 is associated with an improvement of insulin sensitivity and a decrease of @entity165 and @entity1674 in the majority of @entity1 with HAART-associated metabolic alterations and therefore might be an alternative for @entity1 to PI-containing HAART regimens.
